BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 03, 2009
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 2Q09 EPS est 2Q09 EPS actual Outcome Growth from 2Q08 7/31 cls Wk chg % chg Mcap chg 7/31 Mcap
Amgen Inc. (NASDAQ:AMGN) $1.16 $1.29 Beat by $0.13 13% $62.31 $1.39 2% $1,407 $63,081
Revenues for the quarter fell 1% to $3.71B in 2Q08, but beat the Street's estimate of $3.6B. Amgen raised its 2009 adjusted EPS guidance to $4.80-$4.95 from $4.55-$4.75 and said revenues are "trending towards the upper end" of current guidance of $14.4-$14.8B. The Street was expecting 2009 EPS of $4.57 on revenues of $14.3B.
AstraZeneca plc (LSE:AZN; NYSE:AZN) $1.38 $1.64 Beat by $0.26 37% $46.44 -$1.10 -2% -$1,595 $67,338
2Q09 sales increased 9% to $8B. Revenues from the pharma's cardiovascular portfolio increased 30% to $2.1B, including a 33% increase in sales for cholesterol drug Crestor rosuvastatin to $1.1B. Figures are at constant exchange rates. AstraZeneca...

Read the full 1032 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >